Hrynaszkiewicz Iain, Altman Douglas G
Trials. 2009 Mar 18;10:17. doi: 10.1186/1745-6215-10-17.
Many research-funding agencies now require open access to the results of research they have funded, and some also require that researchers make available the raw data generated from that research. Similarly, the journal Trials aims to address inadequate reporting in randomised controlled trials, and in order to fulfil this objective, the journal is working with the scientific and publishing communities to try to establish best practice for publishing raw data from clinical trials in peer-reviewed biomedical journals. Common issues encountered when considering raw data for publication include patient privacy - unless explicit consent for publication is obtained - and ownership, but agreed-upon policies for tackling these concerns do not appear to be addressed in the guidance or mandates currently established. Potential next steps for journal editors and publishers, ethics committees, research-funding agencies, and researchers are proposed, and alternatives to journal publication, such as restricted access repositories, are outlined.
许多研究资助机构现在要求公开其所资助研究的结果,有些还要求研究人员提供该研究产生的原始数据。同样,《试验》杂志旨在解决随机对照试验报告不充分的问题,为实现这一目标,该杂志正与科学界和出版界合作,试图确立在同行评审的生物医学期刊上发表临床试验原始数据的最佳做法。在考虑发表原始数据时遇到的常见问题包括患者隐私(除非获得明确的发表同意)和所有权,但目前制定的指南或指令中似乎并未涉及解决这些问题的商定政策。文中提出了期刊编辑和出版商、伦理委员会、研究资助机构及研究人员可能采取的后续措施,并概述了期刊发表的替代方式,如限制访问的知识库。